Audit a URL →

Sign in Sign up free

Loading…

Weekly · Sunday Morning

Five longevity claims.
Worth your time.
Every Sunday.

Last Sunday

Rapamycin extends mouse lifespan 9–14%
NAD+ precursors reverse aging in humans
Blue-light glasses improve sleep quality
Walking 10 min after meals blunts glucose
Verdict change — caffeine half-life downgraded

5 audits·1 verdict change·0 affiliate links·Every Sunday

Joining 1,247 readers — founders, MDs, and longevity-obsessed people who fact-check their own health decisions.

Browse

Decisions Claims Content Creators

Product

Audit a URL Sunday roundup API (soon)Pricing

About

FAQ Methodology Editorial Standards Corrections Press & brand RSS feed

Legal

Terms of Service Privacy Policy DMCA

Finally, something serious in this space.
Because we actually read the papers.

© 2026 Whalespan. Independent, evidence-graded longevity.

Should children be on GLP-1 weight loss drugs? | Dr. Ralph DeFronzo — Whalespan

Content›Video›Should children be on GLP-1 …

Should children be on GLP-1 weight loss drugs? | Dr. Ralph DeFronzo

Peter Attia6m · 2025-02-26

Claims Made

13

Claims Supported

9

Support Rate

69%

Support rate

9 of 13 claims supported

9 supported4 partial / not

Claims from this content

12

◐Partially SupportedAdolescents with type 2 diabetes exhibit significantly higher insulin resistance compared to adults, contributing to poor drug response.◐Partially SupportedChildhood obesity at age four predicts adult obesity, significantly reduced life expectancy, and significantly reduced quality of life.✕Not SupportedTreating young children with obesity using newer drugs may simply shift addiction from food to drugs without addressing the core issue.◐Partially SupportedApproximately half of patients discontinue weight-loss drugs within a year due to cost and side effects.Partially Supported

More from Peter Attia

Peter Attia on Zone 2 Cardio

Peter Attia on Rapamycin (with Matt Kaeberlein)

Attia walks back the clinic protocol: too aggressive for healthy adults

Discussion

Native comments, Twitter mentions, and Reddit threads about this content — surfaced together so the conversation isn't fragmented across platforms.

M

Share your read of this content…

Posting publicly as you · linked to your social profiles

Sort by:

AV

A. Volkovreader

4h

Bookmarking — the dossier-vs-overview split is the right call. Most of the time I want overview; sometimes I want receipts.

NP

N. Park

2d

Would love a "what would change this verdict" RSS feed. Sign me up if it exists.

◐

The ineffectiveness of current diabetes drugs in adolescents suggests a need to investigate environmental factors contributing to obesogenicity.

◐Partially SupportedDeveloping type 2 diabetes at age 16 may indicate severe underlying genetics and pathology, making current drugs less effective.

◐Partially SupportedThe high prevalence of obesity necessitates identification of subgroups with insulin resistance or metabolic syndrome for targeted treatment.

◐Partially SupportedLong-term management of type 2 diabetes and obesity with drugs like Mounjaro in young patients depends on affordability, patient adherence, and physician expertise.

◐Partially SupportedFor a 16-year-old with an A1C of 9%, lifelong treatment with drugs like Mounjaro is necessary.

◐Partially SupportedGenetic predisposition, obesity, and lack of lean diabetic phenotypes contribute to severe type 2 diabetes in Hispanic youth that is difficult to control.

◐Partially SupportedYoung individuals with type 2 diabetes are developing kidney disease and experiencing myocardial infarctions in their 20s.

◐Partially SupportedAdolescents with type 2 diabetes do not respond well to most diabetes medications, including metformin, sulfonylureas, and GLP-1 agonists, with some response to semaglutide observed.